SMi will present their inaugural conference on Alzheimer’s Disease 2016, which is one of the most threatening diseases that accompanies age, yet formidably mysterious in biology.
This conference will cover: Pre-clinical assessment criteria for AD diagnosis such as risk profiling, population group assessment and stages of AD progression. How do external stimuli play influence studies and outcome?
Furthermore, emerging frontiers in biomarker development to aid more accurate diagnosis and tracking of tau-mediated neuronal death will help further drug development as well as providing more answers into how AD occurs, and most importantly when.
The conference will gather leading researchers and clinical managers to discuss models, diagnostic imaging and novel therapeutic platforms.
For more info visit: http://www.alzheimers-conference.com/bioscreening